Literature DB >> 11368447

Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization.

N C Gutiérrez1, J M Hernández, J L García, M C Cañizo, M González, J Hernández, M B González, M A Garciá-Marcos, J F San Miguel.   

Abstract

To analyze the genomic differences between multiple myeloma (MM) and plasma cell leukemia (PCL), a total of 30 cases were studied by comparative genomic hybridization (CGH). In five cases with a low proportion of plasma cells (PC) in bone marrow, an enrichment of PC was performed by using immunomagnetic beads conjugated with the monoclonal antibody B-B4. In 24 out of the 25 MM (96%) and in all five PCL (100%) patients DNA copy number changes were identified by CGH analysis; in the MM case without chromosomal imbalances, the immunomagnetic enrichment of PC had failed. The most recurrent changes in MM patients were gains at chromosomes 15q (48%), 11q (44%), 3q (40%), 9q (40%) and 1q (36%). By contrast, all PCL patients showed gains in 1q. Losses of chromosomal material were significantly more frequent in PCL than in MM patients (P = 0.03): losses on 13q in 80% of PCL vs 28% of MM; and on chromosome 16 in 80% vs 12%, respectively. In addition, PCL patients showed losses of 2q and 6p that were not present in MM. The CGH data show differences in chromosomal imbalances between MM and PCL.

Entities:  

Mesh:

Year:  2001        PMID: 11368447     DOI: 10.1038/sj.leu.2402116

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

2.  Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Authors:  Daniel W Sherbenou; Blake T Aftab; Yang Su; Christopher R Behrens; Arun Wiita; Aaron C Logan; Diego Acosta-Alvear; Byron C Hann; Peter Walter; Marc A Shuman; Xiaobo Wu; John P Atkinson; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  J Clin Invest       Date:  2016-11-14       Impact factor: 14.808

3.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

Authors:  Ichiro Hanamura; James P Stewart; Yongsheng Huang; Fenghuang Zhan; Madhumita Santra; Jeffrey R Sawyer; Klaus Hollmig; Maurizio Zangarri; Mauricio Pineda-Roman; Frits van Rhee; Federica Cavallo; Bart Burington; John Crowley; Guido Tricot; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-16       Impact factor: 22.113

Review 4.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 5.  Molecular biology of myeloma.

Authors:  N C Gutiérrez; R García-Sanz; J F San Miguel
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

6.  Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia.

Authors:  Yasodha Natkunam; Sara Tedoldi; Jennifer C Paterson; Shuchun Zhao; Manuel Rodriguez-Justo; Andrew H Beck; Reiner Siebert; David Y Mason; Teresa Marafioti
Journal:  Am J Clin Pathol       Date:  2009-09       Impact factor: 2.493

7.  Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Authors:  Jun Inoue; Takemi Otsuki; Akira Hirasawa; Issei Imoto; Yoshinobu Matsuo; Shiroh Shimizu; Masafumi Taniwaki; Johji Inazawa
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 8.  Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy.

Authors:  Jian-Jun Zhao; Ruben D Carrasco
Journal:  Cancer Res       Date:  2014-09-16       Impact factor: 12.701

9.  Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.

Authors:  Elizabeta A Rojas; Luis A Corchete; María Victoria Mateos; Ramón García-Sanz; Irena Misiewicz-Krzeminska; Norma C Gutiérrez
Journal:  Blood Cancer J       Date:  2019-11-20       Impact factor: 11.037

10.  Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context.

Authors:  Pau Ni Ivyna Bong; Ching Ching Ng; Kah Yuen Lam; Puteri Jamilatul Noor Megat Baharuddin; Kian Meng Chang; Zubaidah Zakaria
Journal:  Mol Cytogenet       Date:  2014-04-01       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.